Department of Radiation Oncology, West Virginia University, Morgantown, WV, 26506, USA.
Biomark Res. 2013 Jan 16;1(1):2. doi: 10.1186/2050-7771-1-2.
EGFR inhibition has emerged to be an important strategy in the treatment of non-small cell lung cancer (NSCLC). Small molecule tyrosine kinase inhibitors (TKIs) and mono-clonal antibodies (mAbs) to the EGFR have been tested in multiple large randomized phase III studies alone or combined with chemotherapy, as well as small phase I-II studies which investigated their efficacy as radiosensitizers when combined with radiotherapy. In this review, we described the current clinical outcome after treatment with EGFR TKIs and mAbs alone or combined with chemotherapy in advanced stage NSCLC, as well as the early findings in feasibility/phase I or II studies regarding to whether EGFR TKI or mAb can be safely and effectively combined with radiotherapy in the treatment of locally advanced NSCLC. Furthermore, we explore the potential predictive biomarkers for response to EGFR TKIs or mAbs in NSCLC patients based on the findings in the current clinical trials; the mechanisms of resistance to EGFR inhibition; and the strategies of augmenting the antitumor activity of the EGFR inhibitors alone or when combined with chemotherapy or radiotherapy.
表皮生长因子受体（EGFR）抑制已成为治疗非小细胞肺癌（NSCLC）的重要策略。小分子酪氨酸激酶抑制剂（TKI）和针对 EGFR 的单克隆抗体（mAb）已在多项大型随机 III 期研究中单独或联合化疗进行了测试，以及一些小型 I-II 期研究，这些研究调查了它们与放疗联合作为放射增敏剂的疗效。在这篇综述中，我们描述了单独使用 EGFR TKI 和 mAb 或联合化疗治疗晚期 NSCLC 的临床结果，以及在可行性/ I 或 II 期研究中关于 EGFR TKI 或 mAb 是否可以安全有效地与局部晚期 NSCLC 的放疗联合的早期发现。此外，我们根据当前临床试验的结果探讨了 NSCLC 患者对 EGFR TKI 或 mAb 反应的潜在预测生物标志物；EGFR 抑制耐药的机制；以及单独使用 EGFR 抑制剂或与化疗或放疗联合使用时增强其抗肿瘤活性的策略。
